Welcome to our dedicated page for Noveris Health Sciences news (Ticker: MYCOF), a resource for investors and traders seeking the latest updates and insights on Noveris Health Sciences stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Noveris Health Sciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Noveris Health Sciences's position in the market.
Mydecine Innovations Group (MYCOF) reported financial results for the six months ending June 30, 2022, revealing a net loss of $8.09 million, or $(1.31) per share, an improvement from a loss of $13.53 million in the same period in 2021. As of June 30, 2022, the company held $324,146 in cash. Total assets decreased to $6.19 million from $7.58 million at year-end. Key expenses included substantial costs in corporate development and research, while total liabilities increased to $8.22 million, emphasizing financial challenges. The company continues to focus on advancing mental health treatments.
Mydecine Innovations Group (NEO: MYCO) announced the successful synthesis of short-acting MDMA analogs, named MYCO-006, aimed at enhancing treatment for mental health and addiction disorders. These compounds have a shorter half-life than traditional MDMA, potentially increasing their accessibility in healthcare settings. The company has applied for patent protection with the World Intellectual Property Organization. The new drug is designed to boost therapy effectiveness for conditions like PTSD, addressing significant unmet needs in mental health treatment.
Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) has received FDA clearance for MYCO-001 through an Investigational New Drug (IND) application, marking a key milestone for the company. This enables participation in a $4 million NIH-funded Investigational trial assessing psilocybin’s impact on smoking cessation combined with cognitive-behavioral therapy. The study, led by recognized experts in psychedelic research, follows promising results from earlier trials, with a 80% success rate in smoking abstinence at six months. Mydecine plans to submit an IND for a Phase 2b study using MYCO-001.
Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) announced a corporate update regarding clinical trials and drug development on June 9, 2022. The CEO highlighted progress amid market volatility, noting a reduced burn rate since Q4 2021 and raising $4.5 million in financings. With a shift in clinical strategy to enhance FDA approval chances, the company plans to submit key applications in early Q4 2022. Additionally, Todd Heinzl has been appointed to the Board of Directors, bringing over 30 years of financial experience, strengthening governance.
Mydecine Innovations Group Inc. reported its Q1 2022 financial results, showing a net loss of $5.6 million or $1.20 per share, slightly higher than the previous year's loss of $5.2 million. Total assets decreased to $5.21 million from $7.58 million year-over-year, while total liabilities rose to $8.92 million from $7.37 million. The company achieved a positive FDA pre-IND meeting for its MYCO-001 Smoking Cessation Study and received conditional IRB approval. Mydecine also made progress on their drug development pipeline, focusing on enhancing safety and efficacy in mental health therapeutics.
Mydecine Innovations Group (MYCOF) reported its financial results for the fiscal year ended December 31, 2021, showing a net loss of $28.9 million, a slight increase from $26.9 million the previous year. The company made significant progress in clinical trials, particularly for its MYCO-001 smoking cessation study, having received conditional IRB approval and preparing for full FDA IND application in Q2 2022. Mydecine also advanced its intellectual property portfolio with multiple new patents. As of December 31, 2021, the company had $1.5 million in cash.
Mydecine Innovations Group has received conditional approval from the Institutional Review Board (IRB) for its Phase 2b smoking cessation trial, with Johns Hopkins University as the lead site. The trial aims to evaluate MYCO-001 with hopes of submitting an Investigational New Drug (IND) application to the FDA in Q2 2022. Mydecine aims to be the first commercial IND approved for psilocybin in this indication. The total cost of smoking in the U.S. is over $300 billion annually. The trial’s primary endpoint is six months, with data expected by Q4 2023.
Mydecine Innovations Group (NEO: MYCO, OTC: MYCOF) is a biotechnology firm focused on mental health and addiction treatment. On March 3, 2022, the company announced its participation in three upcoming investor conferences: the 34th Annual Roth Conference (March 13-15), the Oppenheimer Annual Healthcare Conference (March 15-16), and the Maxim Group Virtual Growth Conference (March 28-30). Meetings will discuss the company's clinical trials, patent strategies, and research pipeline. Mydecine is leading a sponsored trial assessing psilocybin for nicotine addiction.
Mydecine Innovations Group (NEO: MYCO) announced a successful meeting with the FDA on February 28, 2022, regarding its Investigational New Drug (IND) and Breakthrough Therapy applications for MYCO-001, aimed at smoking cessation. The drug has shown efficacy rates 2-3 times higher than existing treatments, according to ongoing studies at Johns Hopkins University. The company is preparing its IND submission for the 2B study, expected to launch in March 2022, while Dr. Matthew Johnson will lead the multi-site study.
Mydecine Innovations Group announced positive clinical data for its patent-pending microdose compound, MYCO-005, aimed at addressing cardiovascular risks associated with psilocin analogs. The novel molecule exhibits heart-safe microdosing properties, with research suggesting it binds effectively to the 5-HT2A receptor while avoiding binding to the 5-HT2B receptor, thus reducing cardiac risks. The patent-pending formulation seeks to improve delivery and stability, potentially offering a safer alternative for treating mental health disorders. Mydecine aims to advance its innovative drug discovery pipeline.